BMS news - FiercePharma

BMS: Buyer or buyout target?

May 7, 2008

Market-watchers love to speculate. Their latest topic? Bristol-Myers Squibb, which has been paring away its "non-core" businesses over the last few months. Most recently, Bristol agreed to Read more...

Tags: Bristol-Myers Squibb BMS Astrazeneca Novartis Pfizer

BMS swallows Canada's Erbitux price

April 29, 2008

Call it a new pricing strategy. Bristol-Myers Squibb is preparing to launch the cancer treatment Erbitux in Canada after a two-year wrangle over cost. Approved by Health Canada in September 2005, Read more...

Tags: lung cancer Canada Erbitux BMS Avastin innovation

As former exec indicted, BMS posts growth

April 24, 2008

A triad of Bristol-Myers Squibb news today, some good, some not-so-good. First, let's get the earnings out of the way: The company reported a decline in earnings on restructuring charges, but Read more...

Tags: earnings Plavix Orencia BMS Andrew Bodnar rheumatoid arthritis

BMS, Repligen settle Orencia fight

April 8, 2008

Four companies, two disputed patents, two multimillion-dollar settlements. Repligen and Bristol-Myers Squibb buried the hatchet over Orencia, the rheumatoid arthritis treatment that's been subject Read more...

Tags: BMS Repligen Orencia rheumatoid arthritis Depomed Teva Pharmaceuticals

Courts more open to patent-busting

March 11, 2008

Patents aren't just an issue in Thailand, either. These days, drugmakers are having a more difficult time keeping patent protection on their products, the Financial Times notes. Ever since top U.S. Read more...

Tags: Genentech Generics BMS Contraceptive Yasmin Pfizer lawsuits Bayer

Stopping Plavix may boost heart risks

February 6, 2008

Patients had better be careful when they stop taking the anticlotting drug Plavix. A new study shows that those treated with Plavix for a heart attack or angina had a "rebound effect" risk of heart Read more...

Tags: BMS Adverse events Plavix